Silo Pharma Inc. (NASDAQ: SILO), a developmental-stage biopharmaceutical company, announced that its representatives will attend the IPAC-RS 2026 Nasal Innovation Forum, scheduled for September 16-17, 2026, in Jersey City, New Jersey. The forum provides an opportunity for the company to engage with experts in nasal drug development as it continues to advance SPC-15, its novel nose-to-brain therapeutic for post-traumatic stress disorder (PTSD).
CEO Eric Weisblum emphasized the importance of the forum for Silo Pharma, stating that it offers a platform to discuss the latest advancements in nasal drug delivery. This is particularly relevant as the company progresses SPC-15, which utilizes a targeted delivery approach designed to transport the drug directly to the brain via the nasal route, potentially improving efficacy and reducing systemic side effects.
The announcement follows the release of preclinical data demonstrating that the SPC-15 formulation and its delivery device met predefined specifications for assay, impurities, pH, and microbiological quality over a nine-month period. Additionally, six-month accelerated stability data were consistent and aligned with long-term stability findings, indicating the product's robustness and readiness for further clinical evaluation.
Silo Pharma focuses on addressing underserved conditions, including stress-induced psychiatric disorders, chronic pain, and central nervous system (CNS) diseases. Its portfolio includes SPC-15 for PTSD, SP-26 for fibromyalgia and chronic pain, and preclinical assets targeting Alzheimer's disease and multiple sclerosis. The company's research is conducted in collaboration with leading universities and laboratories, underscoring its commitment to scientific innovation.
The IPAC-RS forum is a key event for professionals involved in inhalation and nasal drug product development, bringing together industry leaders, regulators, and academics to discuss emerging science and regulatory challenges. Silo Pharma's participation highlights its active role in the nasal drug delivery community and its strategic focus on leveraging this route of administration for CNS therapeutics.
For more information about Silo Pharma and its programs, visit the company's website at silopharma.com. The full press release is available at https://ibn.fm/Dy4qf. For the latest news, updates, and financial information, refer to the company's newsroom at https://ibn.fm/SILO.
